Previous 10 | Next 10 |
2023-10-30 08:30:00 ET On October 23, regulators at the Food and Drug Administration (FDA) cleared a key obstacle for Verve Therapeutics (NASDAQ: VERV) , giving it the green light to proceed with an early-stage clinical trial in the U.S. to investigate one of its gene-editing therap...
2023-10-23 07:02:00 ET More on Verve Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Verve gains on u...
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the lifting of the clinical hold and clearance of its Investig...
2023-10-19 03:53:32 ET Summary ARK Invest's 13F portfolio value decreased by 14% to $13.07B this quarter. The top three holdings in the portfolio are Tesla, UiPath, and Coinbase Global. ARK Invest increased its stakes in Block, Twilio, Roblox, Ginkgo Bioworks Holdings, and Rob...
2023-09-26 11:49:39 ET More on Verve Seeking Alpha’s Quant Rating on Verve Therapeutics Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve: Exciting Deal With Eli ...
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that the company will present interim data from its ongoing heart-1...
2023-09-25 04:27:08 ET Summary Verve Therapeutics discloses Q2 2023 results, with the VERVE-101 heart-1 trial on track to deliver initial data by 4Q23. Dr. Frederick T. Fiedorek has been appointed as the new CMO, bringing extensive experience in clinical drug development and cardi...
BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer...
2023-09-18 06:38:07 ET More on Verve Therapeutics Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Verve: Exciting Deal With Eli Lilly, But Still Neutral (Reiterating Hold) Verve Th...
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick “Fred” T. Fiedorek, M.D....
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...